Across TCGA pan-cancer cohorts, LUZP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LUZP2 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LUZP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LUZP2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

OV, LUSC, and COAD are the cancer types where LUZP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.092	0.541	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.140	0.732	.001	12	view →
COAD	DFS	Median	All	1.000	0.502	.022	7	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	OS	Median	All	0.162	0.767	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LUZP2 tumor-vs-normal RNA expression · all LUZP2 data types